Pharmaceutical giant Cipla plans to enter the US market from its China facility in the second half of the current fiscal year, following approval from the US Food and Drug Administration (USFDA), Managing Director and Global CEO Umang Vohra said.

Addressing shareholders in Cipla’s 2023-24 annual report, Vohra said the company is working closely with the USFDA to resolve compliance issues at its other plants. He highlighted that while the Chinese plant has passed its USFDA audit, the company’s plants in Patalganga and Kurkumbh in India have also been given voluntary action-notified status. Meanwhile, the Goa site has received observations and the Indore plant is undergoing remediation.

Vohra also revealed Cipla’s ambitious plans to delve into new therapeutic areas such as obesity-related diseases and liver disorders, while investing heavily in technology-based healthcare solutions. The Mumbai-based company is also focused on combating antimicrobial resistance by developing a strong antimicrobial portfolio, including the launch of the novel Plazomicin injection in India.

(With input from agencies.)